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Platelets are central to thrombus formation, the leading cause of global mortality.1 Antiplatelet drugs are of proven 
benefit for the treatment and prevention of atherothrombotic 
events in many clinical settings, but despite the introduction 
of newer agents in the last decade, important limitations per-
sist. Aspirin and P2Y12 antagonists, the current standard of 
care oral antiplatelet agents in patients with acute coronary 
syndrome, stroke, and peripheral arterial disease, prevent 
thromboxane A2 and ADP platelet activation, respectively.2–7 
However, neither is effective against thrombin, the most 
potent of all platelet agonists,8 and both are associated with an 
increased incidence of bleeding that restricts their use in sen-
sitive populations (eg, elderly, cerebrovascular disease) and 
reduces their net clinical benefit.5,9–12 For many patients, the 
residual risk of atherothrombotic events remains high,5–7,10,13,14 
and there is a clear need for novel agents that can provide 
equivalent (or superior) atherothrombotic efficacy with an 
improved safety profile.
In recent years, PAR4 (protease-activated receptor 4) 
antagonism has emerged as promising new antiplatelet strat-
egy. PAR4 is a G-protein coupled receptor expressed on the 
platelet surface that together with PAR1 (protease-activated 
receptor 1) is responsible for thrombin-mediated platelet 
activation and aggregation.15 Thrombin has a key role in the 
coagulation cascade, but by targeting the platelet receptor 
rather than the protease, this avoids directly interfering with 
thrombin-induced fibrin production. PAR1 has greater affinity 
for thrombin than PAR4, but despite early clinical promise, 
© 2017 The Authors. Arteriosclerosis, Thrombosis, and Vascular Biology is published on behalf of the American Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and 
reproduction in any medium, provided that the original work is properly cited.
Objective—BMS-986120 is a novel first-in-class oral PAR4 (protease-activated receptor 4) antagonist with potent and 
selective antiplatelet effects. We sought to determine for the first time, the effect of BMS-986120 on human ex vivo 
thrombus formation.
Approach and Results—Forty healthy volunteers completed a phase 1 parallel-group PROBE trial (Prospective Randomized 
Open-Label Blinded End Point). Ex vivo platelet activation, platelet aggregation, and thrombus formation were measured 
at 0, 2, and 24 hours after (1) oral BMS-986120 (60 mg) or (2) oral aspirin (600 mg) followed at 18 hours with oral 
aspirin (600 mg) and oral clopidogrel (600 mg). BMS-986120 demonstrated highly selective and reversible inhibition of 
PAR4 agonist peptide (100 μM)-stimulated P-selectin expression, platelet-monocyte aggregates, and platelet aggregation 
(P<0.001 for all). Compared with pretreatment, total thrombus area (μm2/mm) at high shear was reduced by 29.2% (95% 
confidence interval, 18.3%–38.7%; P<0.001) at 2 hours and by 21.4% (9.3%–32.0%; P=0.002) at 24 hours. Reductions 
in thrombus formation were driven by a decrease in platelet-rich thrombus deposition: 34.8% (19.3%–47.3%; P<0.001) at 
2 hours and 23.3% (5.1%–38.0%; P=0.016) at 24 hours. In contrast to aspirin alone, or in combination with clopidogrel, 
BMS-986120 had no effect on thrombus formation at low shear (P=nonsignificant). BMS-986120 administration was not 
associated with an increase in coagulation times or serious adverse events.
Conclusions—BMS-986120 is a highly selective and reversible oral PAR4 antagonist that substantially reduces platelet-rich 
thrombus formation under conditions of high shear stress. Our results suggest PAR4 antagonism has major potential as a 
therapeutic antiplatelet strategy.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT02439190.   
(Arterioscler Thromb Vasc Biol. 2018;38:00-00. DOI: 10.1161/ATVBAHA.117.310104.)
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the addition of vorapaxar (the only licensed PAR1 antagonist) 
to standard care failed to meet its primary efficacy outcome 
in patients with acute coronary syndrome and was associ-
ated with an excess of major bleeding, especially intracranial 
hemorrhage, in phase3 clinical trials.13,16 PAR4 was originally 
thought to simply provide redundancy to PAR1 platelet sig-
naling at high thrombin concentrations.17 However, because of 
differences in activation kinetics and downstream pathways, it 
is now evident that PAR1 and PAR4 have distinct and comple-
mentary roles in the early and late phases of platelet activation 
and aggregation, respectively.18–20 PAR1 activation is brisk but 
transient and requires input from the P2Y12-PI3K (phospha-
tidylinositol 3-kinase) pathway to maintain platelet aggre-
gation.19,20 In contrast, PAR4 is activated at higher thrombin 
concentrations and induces a slow but prolonged intracellular 
signal that acts independently to sustain irreversible aggrega-
tion.17,18,20 Furthermore, PAR4 activation occurs after ADP 
secretion, and thrombin depends on PAR4 but not PAR1 to 
induce full platelet spreading.21 Thus, several lines of evidence 
indicate that although PAR1 and other agonist-signaling path-
ways may be more important for initiating platelet activation, 
the primary role of PAR4 appears to be in sustaining irre-
versible platelet aggregation and thrombus propagation. This 
suggests that PAR4 inhibition may protect against occlusive 
thrombus formation while avoiding interfering with hemo-
static platelet responses to the same extent as PAR1 antago-
nists and other antiplatelet agents.22
BMS-986120 is a first-in-class, oral, highly selective, and 
reversible PAR4 antagonist antiplatelet agent. In preclinical ani-
mal models, BMS-986120 demonstrated potent antithrombotic 
activity with a substantially wider therapeutic window when 
compared with clopidogrel.22 The purpose of the present phase 
1 parallel-group PROBE trial (Prospective Randomized Open-
Label Blinded End Point) was to build on these observations and 
examine for the first time, the antiplatelet and antithrombotic 
effects of BMS-986120 in humans using a translational model 
of ex vivo thrombosis. We determined whether reductions in 
thrombus formation were driven by a decrease in platelet-rich or 
fibrin-rich thrombus formation and whether these effects were 
greater under rheological conditions of low or high shear stress.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
All 40 volunteers (81 volunteers were screened) completed the 
study in full. The demographics and baseline characteristics of 
study volunteers were similar in the 2 treatment groups (Table). 
BMS-986120 was well tolerated with no clinically significant 
effect on any of the biochemical, hematologic, coagulation, 
physical, or ECG safety assessments conducted throughout 
the study (Table I in the online-only Data Supplement). There 
were no serious adverse events. One episode of minor bleed-
ing was reported. This occurred 12 hours after aspirin admin-
istration, self-resolved, and did not recur.
Pharmacokinetic Profile of Oral BMS-986120
BMS-986120 was rapidly absorbed with peak plasma con-
centrations occurring at 2 hours (255±136 ng/mL; Figure 1). 
Plasma concentrations of BMS-986120 were halved by 4 
hours (133±100 ng/mL) and <10% of the peak concentration 
by 24 hours (21±9 ng/mL).
Effect of BMS-986120 on Platelet 
Activation and Aggregation
BMS-986120 demonstrated strong and reversible inhibition 
of PAR4 agonist peptide (AP; 100 μM)-stimulated plate-
let activation and aggregation (P<0.001 for all). Compared 
with pretreatment, PAR4 AP-stimulated increases in plate-
let P-selectin expression (%), platelet-monocyte aggre-
gates (%), and platelet aggregation (%) were reduced by 
91.7% (95% confidence interval [CI], 81.0–102.4), 80.6% 
(95% CI, 68.6%–92.6%), and 85.0% (95% CI, 82.0–88.1) 
at 2 hours and by 53.9% (95% CI, 43.2%–64.7%), 41.1% 
(95% CI, 28.9%–53.2%), and 6.0% (95% CI, 2.9%–9.0%) 
at 24 hours (P<0.001 for all; Figure 2). Plasma concentra-
tions of BMS-986120 correlated with P-selectin expression 
(ρ=−0.87), platelet-monocyte aggregates (ρ=−0.88), and 
platelet aggregation (ρ=−0.82; P<0.001 for all; Figure III 
in the online-only Data Supplement). There was no effect 
on PAR1 AP, ADP, or arachidonic acid platelet responses 
(P=nonsignificant [ns] for all; Figure 2).
Effect of Aspirin±Clopidogrel 
on Platelet Aggregation
Aspirin administration reduced arachidonic acid-stimulated 
platelet aggregation by 74.5% (95% CI, 71.6%–77.3%; 
P<0.001). In combination with clopidogrel, aspirin reduced 
arachidonic acid-stimulated platelet aggregation by 73.7% 
(95% CI, 70.9%–76.5%; P<0.001) and ADP-stimulated 
platelet aggregation by 41.9% (95% CI, 35.2%–48.7%; 
P<0.001), respectively (Figure IV in the online-only Data 
Supplement).
Effect of BMS-986120 on Ex Vivo 
Thrombus Formation
BMS-986120 reduced total thrombus formation at high shear 
(P<0.001) but not at low shear (P=ns; Figure 3). Compared 
with pretreatment, total thrombus area (μm2/mm) at high shear 
was reduced by 29.2% (95% CI, 18.3%–38.7%; P<0.001) at 
2 hours and by 21.4% (95% CI, 9.3%–32.0%; P=0.002) at 24 
hours. Plasma concentrations of BMS-986120 correlated with 
total thrombus formation at high shear (ρ=−0.47; P<0.001) 
but not at low shear (ρ=−0.18; P=ns; Figure III in the online-
only Data Supplement).
Nonstandard Abbreviations and Acronyms
AP agonist peptide
CI confidence interval
ns nonsignificant
PAR protease-activated receptor
PI3K phosphatidylinositol 3-kinase
PROBE prospective randomized open-label blinded end point
TF tissue factor
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Reductions in total thrombus area were driven by a 
decrease in platelet deposition (Figure 4). At high shear, 
platelet-rich thrombus area was reduced by 34.8% (95% CI, 
19.3%–47.3%; P<0.001) at 2 hours and 23.3% (95% CI, 
5.1%–38.0%; P=0.016) at 24 hours. Reductions in fibrin-
rich thrombus area at 2 (−14.7%; 95% CI, −22.5% to −6.2%; 
P=0.002) and 24 hours (−7.9%; 95% CI, −16.3% to 1.4%; 
P=0.09) were small by comparison. BMS-986120 had no 
effect on either platelet-rich or fibrin-rich thrombus formation 
at low shear (P=ns for all).
Effect of Aspirin±Clopidogrel on Ex 
Vivo Thrombus Formation
Aspirin and aspirin in combination with clopidogrel both 
reduced thrombus formation at high and low shear, also 
driven by decrease in platelet-rich thrombus. Aspirin 
reduced total thrombus area and platelet-rich thrombus area 
by 30.2% (95% CI, 15.6%–42.2%; P<0.001) and 41.7% 
(95% CI, 22.9%–56.0%; P<0.001), respectively, and by 
32.4% (95% CI, 18.3%–44.0%; P<0.001) and 46.4% (95% 
CI, 29.1%–59.5%; P<0.001), respectively, when used in 
combination with clopidogrel.
In contrast to BMS-986120, aspirin and aspirin in combi-
nation with clopidogrel both reduced total thrombus area at 
low shear (−17.4%; 95% CI, −27.0% to −6.5%; P=0.003 and 
−13.5%; 95% CI, −23.6% to −2.1%; P=0.02). There was no 
effect on fibrin-rich thrombus deposition at low or high shear 
(P=ns for all).
Discussion
In this phase 1 PROBE designed clinical trial, we have 
shown for the first time that PAR4 antagonism with 
BMS-986120 reduces ex vivo human thrombus formation 
under conditions representative of deep arterial injury in 
a stenosed coronary artery. BMS-986120 demonstrated 
selective and reversible antiplatelet effects with concen-
tration-dependent inhibition of thrombus formation and 
PAR4 AP-stimulated platelet activation and aggregation. 
Our results provide further insights into the role of PAR4 in 
human thrombogenesis and raise major promise for BMS-
986120 as an antiplatelet agent in the treatment and preven-
tion of arterial thrombosis.
Assessment of the antiplatelet and antithrombotic effects 
of PAR4 inhibition has previously been limited by a lack of 
compound specificity and availability.23–25 In comparison with 
earlier compounds, including P4pal-10, YD-3, and its deriva-
tive ML354,25–27 BMS-986120 has antiplatelet activity against 
α thrombin, demonstrated greater potency and selectivity of 
effect in preclinical and phase 1 studies of platelet inhibition, 
and is the first orally bioavailable PAR4 antagonist.22,28 In the 
present study, a single dose of BMS-986120 resulted in near 
complete inhibition of PAR4 AP-stimulated platelet activa-
tion and aggregation at 2 hours, with a return toward base-
line at 24 hours. Importantly, there was no effect on PAR1 
AP, ADP, or arachidonic acid-stimulated platelet activity. Our 
data, therefore, add to previous studies indicating that BMS-
986120 is a highly selective and reversible antiplatelet agent 
with potent activity against PAR4-stimulated platelet activa-
tion and aggregation in humans.
The antithrombotic effects of BMS-986120 in humans 
were examined using the Badimon perfusion chamber—a 
well validated model for measuring ex vivo thrombus forma-
tion in humans.29–36 Using the same model and under the same 
flow conditions, previous studies in healthy volunteers have 
demonstrated reductions in high shear thrombus formation of 
18.7% after a single 300-mg oral dose of clopidogrel, 28% 
with a 60-mg oral dose of edoxaban and 56% with extracor-
poreal coadministration of tirofiban (50 ng/mL).29,36,37 In the 
present study, a single dose of BMS-986120 (60 mg) reduced 
high shear thrombus formation by nearly a third. This is con-
sistent with preclinical animal data22,23 and comparable with 
reductions in thrombus formation we observed with high load-
ing doses of aspirin and clopidogrel. Importantly, therefore, 
we have shown that oral PAR4 antagonism with BMS-986120 
substantially reduces ex vivo human thrombus formation. 
Moreover, reductions were similar in magnitude to clinically 
approved antiplatelet agents suggesting a high probability of 
in vivo antithrombotic efficacy.
Table. Baseline Characteristics of Study Volunteers
Test Variable
BMS-986120 
(n=20)
Aspirin±Clopidogrel 
(n=20)
Men (%) 20 (100) 20 (100)
Age, y (SD) 23.6 (3.4) 28.7 (10.0)
BMI, kg/m2 (SD) 23.6 (2.6) 25.4 (3.5)
Race (%)
  White 19 (95) 19 (95)
  Black/African 1 (5) 0
  Asian 0 1 (5)
Hemoglobin, g/dL (SD) 14.2 (0.42) 14.6 (0.85)
Platelet count, ×109 c/L (SD) 230 (45) 221 (49)
APTT, s (SD) 30.9 (2.2) 30.8 (2.6)
PT, s (SD) 12.3 (0.9) 11.9 (0.7)
APTT indicates activated partial thromboplastin time; BMI, body mass index; 
and PT, prothrombin time.
Figure 1. Pharmacokinetics of BMS-986120. BMS-986120 was 
rapidly absorbed with a half-life of 4 h. Data shown are mean 
plasma concentrations of BMS-986120 (±95% confidence inter-
vals) after administration of a single oral 60-mg dose.
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Figure 2. BMS-986120 demonstrated highly selective, potent, and reversible inhibition of PAR (protease-activated receptor) 4-stimulated 
platelet activation and aggregation. Box plots of platelet activation and aggregation in response to (A–C) PAR4 Agonist peptide (AP; 100 
μM), (D and E) PAR1 AP (100 μM), (F) PAR1 AP (25 μM), (G) ADP (10 μM), and (H) arachidonic acid (AA; 5 mmol/L), in volunteers (Continued )
 by guest on January 12, 2018
http://atvb.ahajournals.org/
D
ow
nloaded from
 
Wilson et al  BMS-986120 Inhibits Human Thrombus Formation  5
BMS-986120 seemed to have less of an effect on throm-
bus formation at low shear than either aspirin alone or aspirin 
in combination with clopidogrel. Although further studies are 
required to confirm whether PAR4 antagonism is more selec-
tive for inhibiting thrombus formation at high shear than exist-
ing agents, distinct mechanisms of platelet aggregation are 
known to operate under different rheological conditions.38,39 
Low shear rates reflect flow conditions found in patent epi-
cardial arteries and some veins, whereas the majority of ath-
erothrombotic events invariably occur at areas of high shear 
stress seen in diseased arteries.40,41 Indeed, most myocardial 
infarctions arise from stenotic atherosclerotic plaques with 
rheological conditions comparable with those in our high 
shear chamber.42–44 Antiplatelet agents that are more selective 
for inhibiting thrombus formation at high shear may allow at-
risk vascular beds to be targeted with greater specificity. Given 
many treatment-related bleeding events are likely to occur 
from vessels with low shear rates,45–49 this could facilitate a 
wider safety profile.
As expected from an antiplatelet agent, reductions in 
thrombus were driven by a decrease in platelet deposition; 
however, there was also a small but significant reduction in 
fibrin-rich thrombus formation. PAR4 is reported to be the 
predominant platelet PAR responsible for phosphatidylser-
ine exposure, microparticle shedding, and thrombin genera-
tion.50 Our results add to these studies, indicating that PAR4 
may have a role in platelet procoagulant activity during ex 
vivo human thrombus formation. Whether this is beneficial or 
not is uncertain, but it is worth noting BMS-986120 was not 
associated with an increase in coagulation assay times, and 
no bleeding-related clinical findings or adverse events were 
reported in a previous phase 1 single- and multiple-ascending 
dose study.28
PAR4 is expressed within the vasculature, and PAR4 
antagonism may, in addition to protecting against throm-
bosis, serve to limit vascular complications in at-risk 
patients. Human vascular smooth muscle cells upregulate 
PAR4 in response to glucose,51 and elevated expression of 
A
B C
Figure 3. BMS-986120 reduced thrombus formation at high shear but not at low shear. A, Representative image of porcine aortic media 
exposed to human blood at high shear stained to quantify total thrombus area. Sections were stained with polyclonal goat antihuman 
fibrin(ogen) antibody and CD61 monoclonal mouse antihuman antibody before treatment with 3,3′-diaminobenzidine substrate chromo-
gen. Sections were then counterstained with a modified Masson trichrome (hematoxylin and sirius red, 0.1%). Effect of (B) BMS-986120 
and (C) aspirin (ASA)±clopidogrel (Clop.) on total thrombus area at high and low shear. Statistical comparisons (least significance differ-
ence test) vs 0 h are represented above each plot. ns indicates nonsignificant. *P<0.05, **P<0.01, ***P<0.001.
Figure 2 Continued. randomized to BMS-986120. Data shown are the adjusted mean (+) normalized to unstimulated values. The line 
within the box represents the median, upper and lower edges of the box represent the 75th and 25th percentiles, and upper and lower 
whiskers represent the 95th and 5th percentiles. Statistical comparisons (least significance difference test) vs 0 h are represented above 
each plot. ns indicates nonsignificant. *P<0.05, **P<0.01, ***P<0.001.
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PAR4 has been reported in the tunica media of atherec-
tomy and saphenous vein tissue from patients with diabetes 
mellitus.51 Moreover, PAR4 deficiency protected against 
excessive remodeling induced by carotid artery ligation in 
streptozotocin-diabetic mice.52 PAR4, therefore, seems to 
be a key regulator of exaggerated intimal thickening in diabe-
tes mellitus, and future studies examining the antiproliferative 
potential of PAR4 antagonism would be of significant thera-
peutic interest.
Our study has some limitations. First, although the 
exposed porcine aortic media presents many of the common 
constituents of a disrupted atherosclerotic plaque, includ-
ing type I collagen, it may not contain tissue factor (TF).53–55 
TF activates the coagulation cascade and is an important 
Figure 4. Reductions in thrombus formation were driven by a decrease in platelet-rich thrombus formation. Representative image of 
thrombus formed at high shear stained to allow quantification of (A) platelet-rich and (B) fibrin-rich thrombus area. Sections were stained 
with polyclonal goat antihuman fibrin(ogen) antibody and CD61 monoclonal mouse antihuman antibody before counterstaining with tyra-
mide Cy3 and FITC. Effect of (C) BMS-986120 and (D) aspirin (ASA)±clopidogrel (Clop.) on platelet and fibrin deposition at low and high 
shear. Data shown are adjusted means±95% confidence intervals. Statistical comparisons (least significance difference test) vs 0 h are 
represented above each plot. ns indicates nonsignificant. *P<0.05, **P<0.01, ***P<0.001.
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contributor to thrombogenicity.56,57 Nevertheless, this does 
not overly limit our model for the assessment of thrombosis 
because binding of blood-borne circulating TF is sufficient 
to allow activation of the coagulation cascade and thrombus 
propagation.53,54,58–60 Indeed, previous studies have demon-
strated that thrombus formed from human blood perfused 
over exposed porcine tunica media (devoid of TF) stains 
heavily for TF.53,54 Second, we assessed a single oral dose 
of BMS-986120 and did not explore the effect of prolonged 
BMS-986120 administration on thrombus formation, such 
as would occur with the secondary prevention of myocardial 
infarction and stroke. However, because this was the phase 1 
trial designed to examine the antithrombotic effects of oral 
PAR4 antagonism in humans for the first time, we felt our 
study design was appropriate. Third, BMS-986120 was dosed 
in isolation, and future studies to determine the antiplatelet 
and antithrombotic effects of PAR4 antagonism in combina-
tion with current agents would be of interest. Finally, although 
no episodes of bleeding occurred in volunteers administered 
BMS-986120 and BMS-986120 was not associated with an 
increase in bleeding times in a previous phase 1 safety and 
tolerability study,28 the safety profile of PAR4 antagonism in 
humans remains to be defined.
In conclusion, we have demonstrated that PAR4 antago-
nism with BMS-986120—a highly selective and reversible 
oral PAR4 antagonist—substantially reduces ex vivo throm-
bus formation in healthy volunteers under conditions of high 
shear stress. BMS-986120 was well tolerated with no change 
in coagulation assays or serious adverse events. Given the 
potential hemostatic sparing effects of PAR4 antagonism, 
our results suggest that BMS-986120 has major potential as a 
novel antiplatelet agent and that further investigation in clini-
cal trials is warranted.
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Highlights
• Inhibition of thrombin-mediated platelet activation through PAR4 (protease-activated receptor 4) antagonism represents a promising new 
antiplatelet strategy because of the potential for reduced bleeding.
• BMS-986120 is a first-in-class, oral, highly selective, and reversible PAR4 antagonist antiplatelet agent.
• A single dose of BMS-986120 substantially reduced ex vivo thrombus formation in healthy volunteers under conditions of high shear stress, 
driven by a reduction in platelet-rich thrombus deposition.
• Our results suggest PAR4 antagonism with BMS-986120 holds major promise as a novel antiplatelet strategy because of the potential for a 
wider therapeutic window in terms of antithrombotic efficacy and bleeding risk.
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Figure	I.	Schema/c	overview	of	study	design.
0 h 2 h 24 h
BMS-986120 60 mg
0 h 2 h 24 h
Aspirin 600 mg Aspirin 600 mg + 
Clopidogrel 600 mg
18 h
P, T P, T P, T
Treatment Arm A (n=20)
Treatment Arm B (n=20)
Follow up 
telephone call  
at 8 days
Randomisation 
(1:1)
Screening visit (≤ 14 
days before treatment)
P = platelet studies; T = perfusion chamber
P, T P, T P, T
Table	I.	Safety	Assessments	
Test	variable BMS-986120	(n=20) Aspirin	±	Clopidogrel	(n=20)
0	hour 2	hour 24	hour 0	hour ASA ASA	+	Clop
ALT,	U/L	(SD) 19.0	(6.1) 18.7	(6.2) 		17.8	(6.4)** 26.3	(14.8) 25.9	(14.2) 25.4	(13.3)
AST,	U/L	(SD) 20.7	(4.6) 20.9	(5.7) 			18.0	(3.6)*** 23.6	(7.4) 23.4	(6.8) 		21.0	(4.5)**
Bilirubin,	mg/dL	(SD) 0.70	(0.3) 0.80	(0.3)* 0.62	(0.3) 0.76	(0.2) 0.73	(0.2) 		0.66	(0.2)**
CreaEne	Kinase,	U/L	(SD) 197	(190) 187	(188) 			115	(83)*** 186	(144) 171	(128) 			108	(61)***
Urea,	mmol/L	(SD) 5.1	(0.96) 		4.6	(0.76)** 			4.1	(0.77)*** 5.0	(1.0) 4.7	(0.93) 		4.5	(0.98)**
CreaEnine,	mg/dL	(SD) 0.83	(0.06) 0.81	(0.09) 0.82	(0.08) 0.89	(0.11) 0.86	(0.09) 0.86	(0.10)
Haemoglobin,	g/dL	(SD) 14.2	(0.4) 14.2	(0.4) 14.2	(0.3) 14.6	(0.8) 14.4	(0.8) 14.3	(1.3)
Platelet	count,	x109	c/L	(SD) 229	(45) 227	(46) 228	(46) 221	(49) 220	(50) 216	(53)
APTT,	seconds	(SD) 30.9	(2.1) 30.3	(2.7) 30.4	(2.1) 30.8	(2.5) 30.3	(3.3) 30.1	(2.9)
PT,	seconds	(SD) 12.3	(0.9) 12.3	(0.9) 12.1	(0.8) 11.9	(0.7) 12.3	(0.7)** 12.1	(0.7)
QTCf	interval,	milliseconds	(SD) 405	(11.8) 411	(17.9) 405	(15.9) 401	(16.3) 402	(13.4) 399	(10.8)
Data	shown	are	the	adjusted	means	with	standard	deviaEon.	All	significant	differences	(Least	Significance	Difference	test)	versus	0	hour	are	presented:	*	p<0.05,	
**	p<0.01,	***	p<0.001.	AbbreviaEons	used:	ASA,	aspirin;	Clo,	clopidogrel.	ALT,	alanine	transaminase;	ASA,	Aspirin;	AST,	aspartate	transaminase;	APTT,	acEvated	
parEal	thromboplasEn	Eme;	Clop,	Clopidogrel;	PT,	prothrombin	Eme;	QTCf,	QTC	interval	corrected	for	heart	rate	by	Fridericia's	formula;	and	SD,	standard	
deviaEon
Figure	II.	Correla/ons	between	plasma	concentra/ons	of	BMS-986120	and	selected	study	endpoints.	
Data	shown	are	sca]er	plots	of	[A]	PAR4	AP	sEmulated	p-selecEn	expression,	[B]	PAR4	AP	sEmulated	platelet-monocyte	aggregates,	[C]	PAR4	
AP	sEmulated	platelet	aggregaEon,	[D]	total	thrombus	area	at	high	shear,	and	[E]	total	thrombus	at	low	shear	in	volunteers	randomised	to	
BMS-986120.	CorrelaEon	coefficients	(𝜌)	and	p-values	were	determined	by	Spearman’s	rank-order	correlaEon.	
PAR4	AP	S/mulated	Platelet	Responses
[A]	P-SelecEn	Expression	% [B]	Platelet-Monocyte	Aggregates	(%) [C]	Platelet	AggregaEon	(%)
Total	Thrombus	Area
[D]	High	Shear [E]	Low	Shear
𝜌	=	-0.87	
p	<	0.001
𝜌	=	-0.88	
p	<	0.001
𝜌	=	-0.82	
p	<	0.001
𝜌	=	-0.47	
p	<	0.001
𝜌	=	-0.18	
p	=	0.18
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Figure	III.	Box	plots	of	platelet	aggrega/on	in	response	to	(A)	arachidonic	acid	[5	mM]	and	(B)	adenosine	diphosphate	
[10	µM]	in	volunteers	randomised	to	aspirin	±	clopidogrel.	
Data	shown	are	the	adjusted	means	(+)	normalised	to	unsEmulated	values.	The	line	within	the	box	represents	the	median,	
upper	and	lower	edges	of	the	box	represent	the	75th	and	25th	percenEles,	and	upper	and	lower	whiskers	represent	the	
95th	and	5th	percenEles.	StaEsEcal	comparisons	(Least	Significance	Difference	test)	versus	0	hour	are	shown	above	each	
plot:	*	p<0.05,	**	p<0.01,	***	p<0.001.
Platelet	Aggrega/on
[A]	Arachidonic	Acid	5	mM [B]	Adenosine	Diphosphate	10	uM
0 hour ASA ASA + Clop.
Time Point
Unstim.
100% 
*** ***
0 hour ASA + Clop.
Time Point
Unstim.
100% 
***
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SUPPLEMENTAL MATERIAL 1	
 2	
Methods 3	
 4	
Study Design 5	
This was a phase I parallel group (n=20 per treatment arm) prospective 6	
randomized open-label blinded endpoint (PROBE) trial conducted at a single 7	
site (Clinical Research Facility, Royal Infirmary of Edinburgh, Scotland) 8	
between the 23rd September 2015 and 1st March 2016. Ex vivo platelet 9	
aggregation, platelet activation and thrombus formation were measured at 0 10	
(pre-treatment), 2 and 24 h after oral administration of (a) 60 mg of BMS-11	
986120 or (b) 600 mg aspirin with a second 600 mg aspirin and 600 mg 12	
clopidogrel at 18 h (Figure I in the online-only Data Supplement). Aspirin ± 13	
clopidogrel were included as a positive control and assay validation tool.  14	
 15	
The trial was sponsored by Bristol-Myers Squibb (BMS) and was designed 16	
collaboratively with the host academic center. The study was approved by the 17	
local research ethics committee, conducted in accordance with the 18	
Declaration of Helsinki and with the written informed consent of all volunteers. 19	
Clinical Trial Authorization was provided by the Medicines and Healthcare 20	
products Regulatory Authority (MHRA) of the United Kingdom. 21	
 22	
Study End-Points 23	
The primary outcome was the effect of BMS-986120 on total thrombus area 24	
as compared to pre-treatment. Secondary and exploratory end-points 25	
included the effect of study drug (BMS-986120 or aspirin ± clopidogrel) on 26	
platelet aggregation, p-selectin expression, platelet-monocyte aggregates, 27	
and thrombus composition (platelet- and fibrin-rich thrombus area). 28	
 29	
Study Population 30	
Healthy non-smoking male and female volunteers between the ages of 18 and 31	
65 years (inclusive) and with a body mass index (BMI) of 18 to 32 kg/m2 32	
underwent screening including detailed medical history, physical examination, 33	
laboratory blood tests, urinalysis and 12-lead electrocardiogram (ECG). 34	
Exclusion criteria were women of child-bearing potential and any clinically 35	
significant coexisting condition including hypertension, hyperlipidemia, 36	
diabetes mellitus, gastrointestinal disease that could affect drug absorption, 37	
coagulopathy, recent infective or inflammatory condition, known liver disease 38	
or screening blood tests indicative of renal, liver, clotting, thyroid or 39	
hematological abnormality. Volunteers must not have been taking any 40	
prescription medications for 4 weeks, over-the-counter medications, herbal 41	
supplements and vitamins for 1 week, and alcohol or caffeine containing 42	
products for 72 hours prior to and for the duration of the study. 43	
 44	
Dose Selection 45	
BMS-986120 is a competitive, reversible inhibitor of PAR4 AP induced platelet 46	
aggregation (Kon=0.12 ± 0.043 nM-1min-1, Koff=0.0082 ± 0.0016 min-1, 47	
Kd=0.098 ± 0.016 nM). In cynomolgus monkeys, BMS-986120 demonstrated 48	
dose-dependent (0.2-1.0 mg/kg) preservation of carotid arterial flow following 49	
	 2	
electrolytic injury at the expense of a slight increase in mesenteric and kidney 1	
bleeding times1. In a single ascending (0.5-180 mg) and multiple ascending 2	
dose study (2.5-100 mg daily for up to 14 days) in healthy volunteers, BMS-3	
986120 was found to be safe and well tolerated with complete and reversible 4	
inhibition of PAR4 agonist peptide (AP) stimulated platelet aggregation at ≥10 5	
mg daily2. On the basis of these studies, a 60 mg dose was selected for the 6	
present phase 1 trial as this was calculated to be sufficient to inhibit platelet 7	
aggregation 2 h post dose and would be at the edge of a potential 8	
pharmacodynamic effect at 24 h. This would allow for “dose ranging” with a 9	
single dose of BMS-986120 whilst remaining well within the safety 10	
experience.  11	
 12	
Doses of aspirin (600 mg) and clopidogrel (600 mg) were selected to reflect 13	
the maximal antithrombotic efficacy that might reasonably be expected in 14	
clinical practice following initiation of these antiplatelet agents in an acute 15	
setting.  16	
 17	
Study Outcome Measures 18	
Blood Sampling and Agonists 19	
All blood samples for pharmacodynamic and pharmacokinetic assessments 20	
were drawn uncuffed through a 17G cannula in the ante-cubital fossa. For 21	
each time point, the first 2.5 mL of blood was discarded. PAR1 and PAR4 APs 22	
(SFLLRN and A-Phe(4-F)-PGWLVKNG respectively) were provided by 23	
Bristol-Myers Squibb (Princeton, USA), adenosine diphosphate (ADP) by 24	
Sigma-Aldrich (Gillingham, UK) and arachidonic acid (AA) by Alpha 25	
Laboratories (Eastleigh, UK). 26	
 27	
Pharmacokinetic Assessment 28	
Plasma concentrations of BMS-986120 were determined at 0, 1, 2, 3, 4, 5, 6, 29	
9 and 24 h post treatment using a validated liquid chromatography tandem-30	
mass spectrometry (LC-MS/MS) method with a lower limit of quantification 31	
(LLQ) of 0.250 ng/mL, with an accuracy coefficient of variation of <5 % and 32	
precision (intra- and inter-assay) coefficients of variation of <10 %. Blood 33	
samples were collected into 3 mL K2EDTA vacutainers (Becton-Dickinson, 34	
Cowley, UK) and placed on wet ice. Within 1 h of collection, samples were 35	
centrifuged at 1200 g (2-8 °C) for 10 min. Plasma was decanted and stored at 36	
-20 °C before analysis. 37	
 38	
Platelet Aggregation 39	
Platelet aggregation was assessed by optical aggregometry (PAP-8E; 40	
Bio/Data Corp, Horsham, PA, USA) of platelet-rich plasma (PRP). To obtain 41	
PRP, 18 mL of blood was collected, mixed immediately with 2 mL of 3.8 % 42	
sodium citrate, and then centrifuged at 300 g (room temperature) for 15 min. 43	
For reference, 2 mL of PRP was centrifuged at 5500 g for 6 min to obtain 44	
platelet-poor plasma (PPP). All samples were allowed to equilibrate for 10 min 45	
(37 °C) after the addition of agonist and the peak aggregation recorded. 46	
 47	
Platelet Activation 48	
Platelet p-selectin expression and platelet-monocyte aggregates were 49	
determined by flow cytometry. Blood (5 mL) was collected into 50 µL of 75 50	
	 3	
mM D-phenylalanyl-L-propyl-L-arginine chloromethylketone (PPACK; Enzo 1	
Life Sciences, Exeter, UK) then immediately aliquoted into eppendorfs pre-2	
filled with or without agonist and the following conjugated monoclonal 3	
antibodies: allophycocyanin (APC)-conjugated CD14, phycoerythrin (PE)-4	
conjugated CD62P and fluorescein isothiocyanate (FITC)-conjugated CD42a 5	
(Becton-Dickinson). All antibodies were diluted 1:10. Samples were incubated 6	
for 20 min at room temperature before fixing with 1 % paraformaldehyde (p-7	
selectin) or FACS-Lyse (Becton-Dickinson; platelet-monocyte aggregates). All 8	
samples were analysed within 24 h using a FACSCalibur flow cytometer 9	
(Becton-Dickinson). Data analysis was performed using FlowJo v10 (Treestar, 10	
Oregon, USA). 11	
 12	
Ex Vivo Perfusion Model of Thrombosis 13	
The effect of study compound on ex vivo thrombus formation was assessed 14	
using the Badimon perfusion chamber as previously described3. In brief, a 15	
pump was used to draw native (unanticoagulated) blood directly from an 16	
antecubital vein through a series of three cylindrical perfusion chambers 17	
maintained at 37°C in a water bath. Each chamber contained a strip of 18	
porcine aorta from which the intima and a thin layer of media had been 19	
removed. The ultrastructure of porcine aorta closely resembles that of human 20	
arteries and by removing the intima and a thin layer of media, blood is 21	
exposed to collagen fibres (type I and type III), proteoglycans, basement 22	
membrane, elastin, smooth muscle cells and other constituents common to an 23	
atherosclerotic plaque4-8. Rheological conditions in the first chamber were set 24	
to simulate those of patent medium-sized coronary arteries (inner lumen 25	
diameter, 2.0 mm; vessel wall shear rate, 212 s-1; mean blood velocity, 5.3 26	
cm/s; Reynolds number: 30), whereas those in the second and third 27	
chambers simulate those of mild to moderately stenosed coronary arteries 28	
(inner lumen diameter, 1.0 mm; vessel wall shear rate: 1690 s-1; mean blood 29	
velocity, 21.2 cm/s; Reynolds number: 60). Shear conditions at the vessel wall 30	
were calculated from the expression for shear rate given for a Newtonian fluid 31	
in tube flow9,10. Each study lasted for exactly 5 min during which flow was 32	
maintained at a constant rate of 10 mL/min. All studies were performed using 33	
the same perfusion chamber and by the same operator. 34	
 35	
Histomorphometric Analysis 36	
As thrombus forms along the entire length of the exposed porcine aortic strip, 37	
the mean transverse cross-sectional area gives a reliable reflection of total 38	
thrombus6. Following fixation, the proximal and distal 1 mm of the exposed 39	
substrate were discarded and the remainder cut into eight segments. 40	
Individual segments were then embedded in paraffin wax from which 4-µm 41	
sections were prepared for histomorphometric analysis. 42	
 43	
To detect total thrombus area, endogenous hydrogen peroxide activity was 44	
blocked using 3 % hydrogen peroxide solution (Leica Microsystems GmbH, 45	
Wetzlar, Germany) for 5 minutes. Sections were then incubated at room 46	
temperature for 1 hour with polyclonal rabbit anti-human fibrin(ogen) antibody 47	
(1.2 µg/mL, Dako, Glostrup, Denmark; Cat. No. A0080) and monoclonal 48	
mouse anti-human CD61 antibody (1.28 µg/ml, Dako; Cat. No. M0753). 49	
Antigen visualisation was performed using a Bond Polymer refine detection kit 50	
	 4	
(Leica Microsystems GmbH) and treatment with 3,3'-diaminobenzidine 1	
substrate chromogen (66 mM, Dako). Finally, sections were counterstained 2	
with a modified Masson’s trichrome (hematoxylin and sirius red 0.1 %; Figure 3	
II in the online-only Data Supplement). 4	
 5	
To examine the effect of study drug(s) on fibrin-rich and platelet-rich thrombus 6	
formation, endogenous hydrogen peroxide activity was blocked using 3 % 7	
hydrogen peroxide solution (VWR, Radnor, PA, USA) for 10 min and non-8	
specific binding blocked using 20 % normal goat serum (Biosera, Nuaille, 9	
France) in Tris-Buffered Saline with 0.01% Tween (TBST)). Sections were 10	
then incubated with polyclonal rabbit anti-human fibrin(ogen) antibody (1.2 11	
µg/ml) to detect fibrin and CD61 monoclonal mouse anti-human antibody 12	
(0.32 µg/ml) to detect platelets. Following TBST washes, goat anti-rabbit 13	
peroxidase (1:500; Abcam, Cambridge, UK) was applied and the presence of 14	
antigen visualized with Tyramide Cy3 (1:50; Perkin Elmer, Boston, MA, USA; 15	
Cat. no. NEL744B001KT) and FITC (1:50; Perkin Elmer, Waltham, MA, USA; 16	
Cat. no. NEL741B001KT) before nuclear counterstaining with DAPI (5 µg/ml; 17	
Sigma-Aldrich; Cat. No. D9542). 18	
 19	
Prior to the first experimental sample, non-specific binding of the primary 20	
antibodies was excluded using tissue negative controls (perfusion chamber 21	
porcine sections exposed to saline rather than blood). To ensure staining for 22	
platelets and fibrin(ogen) antigen was the result of detection of the antigen, 23	
secondary antibody controls (with the primary antibody absent) were run in 24	
parallel for each volunteer. No labelling was observed.  25	
 26	
A semi-automated slide scanner (Axioscan Z1; Zeiss, Jena, Germany) and 27	
image analysis software (Definiens, Munich, Germany) were used by a 28	
blinded operator to quantify thrombus area and composition. Digital images of 29	
each section were acquired at ×20 magnification. High-resolution classifiers 30	
based on colour were established to detect total thrombus, platelet and fibrin 31	
area.  32	
 33	
Safety and tolerability 34	
The primary safety end-point was the incidence of serious adverse events 35	
(SAEs) or death during and for up to 30 days post dosing. Adverse events 36	
(AEs) not meeting the SAE threshold were also recorded. All volunteers 37	
received telephone follow up on day 8. Reports of SAEs and AEs could 38	
originate from the volunteer, investigator or study personnel. Additional safety 39	
endpoints included changes in hematological and biochemical indices, 40	
hematuria (including microhematuria), alteration in the 12-lead 41	
electrocardiogram (ECG), or abnormal findings on physical examination 42	
performed at baseline, 2 and 24 h post dosing.  43	
  44	
Statistical Analysis 45	
Following study completion, the database was locked and all statistical 46	
analyses carried out independent of the sponsor. The demographic and 47	
baseline characteristics of volunteers are expressed as mean ± standard 48	
deviation (SD) for continuous variables and percentages for categorical 49	
variables. The effect of study drug(s) on endpoints was assessed by general 50	
	 5	
linear mixed effects models, with perfusion procedure (baseline, 2 and 24 h) 1	
as fixed effects and subjects as random effects. Mean within-subject 2	
differences for the change from baseline were generated and analysed using 3	
the Least Significance Difference (LSD) test. Prior to model fitting, total 4	
thrombus area, platelet area and fibrin area were log-transformed. 5	
Associations between plasma concentrations of BMS-986120 and study end-6	
points were determined by Spearman’s rank-order correlation (ρ). Two sided 7	
p-values of ≤0.05 were considered statistically significant. Analyses were 8	
performed using SPSS version 21.0 (IBM Corp., Armonk, New York) and R 9	
version 3.3.1 (R Project for Statistical Computing, Vienna, Austria). 10	
 11	
 12	
 13	
  14	
	 6	
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